TCM-based therapy for coronary disorders - China Pharma HoldingsAlternative Names: TCM for coronary heart disease - China Pharma Holdings; Traditional Chinese Medicine - China Pharma Holdings
Latest Information Update: 19 Apr 2016
At a glance
- Originator China Pharma Holdings
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Coronary disorders